Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon to Use BioSeek Tools for Drug Discovery

NEW YORK (GenomeWeb News) – BioSeek said today that Lexicon Pharmaceuticals will use the firm’s BioMAP systems to evaluate selected compounds associated with Lexicon’s drug discovery programs.
 
The BioMAP systems use predictive primary human cell-based disease models that generate profiles for drug candidates.
 
“By providing predictive preclinical human data on the pharmacological properties of Lexicon's compounds, the BioMAP platform can help to discern the relevant physiologic pathway impacted by the compounds and identify appropriate cellular assays for their further optimization,” Michael venuti, CEO of BioSeek, said in a statement.
 
Terms of the deal were not disclosed.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.